Skip Navigation

Radiation Treatment Pharmaceuticals

ORAU Offers Clinical Information about Drugs for Treating Internal Radiation Exposure

Pharmaceuticals for treating internal radiation exposure

Internal radiation exposure, though rare, is a serious concern. But in the event of a radiological incident, ORAU is a valuable resource in the use of drug therapies to treat radiation incident victims.

We maintain a repository of clinical information and provide data to practitioners worldwide on calcium and zinc diethylenetriaminepentaacetic acid (DTPA) and ferric hexacyanoferrate, also known as Prussian Blue.

Calcium-DTPA and zinc-DTPA are injectable chelating agents used to enhance the excretion of plutonium and other transuranics from the body. Prussian Blue binds to radioactive cesium and thallium in the stomach, thereby enhancing their excretion from the body.

ORAU personnel are also familiar with the use of other treatments such as potassium iodide (KI). If radioactive iodine is released into the air during a radiation event and then inhaled, it is quickly absorbed by the thyroid gland and can cause damage. KI acts to block the radioactive iodine from being taken into the thyroid gland, thus protecting this gland from injury.